PURA Sales and Production NOT IMPACTED by Coronavirus - COVID-19
February 28 2020 - 9:54AM
InvestorsHub NewsWire
PURA Sales and Production NOT
IMPACTED by Coronavirus – COVID-19
Dallas, TX -- February 28, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced the Coronavirus is not impacting PURA
sales or production. In light of the public market
performance reportedly in reaction to Coronavirus concerns, PURA
management believed it worthwhile to emphasize that the Coronavirus
has had no impact on PURA.
In spite of the recent market performance
reportedly in reaction to the Coronavirus, PURA yesterday announced
the acquisition of a CBD Infused Pet Products operation. The
seller currently provides concierge pet services through an online
portal and the CBD Infused Pet Product Line will bear the name of
the portal. PURA will have access to the portal and the
existing customer base in conjunction with the purchase
agreement. The CBD pet products
market is anticipated to reach $1.16 billion in
the U.S. alone by 2022. PURA management plans to release more
details on the CBD Infused Pet Product launch
soon.
The CBD Infused Pet Products acquisition
is the first in an anticipated series of acquisitions. PURA
recently launched a campaign to acquire CBD infused beverage,
edible and topical operations and also announced closing on a $5
million investment to fund the acquisition campaign. The $5 million
investment is structured as a debt facility whereby funds can be
drawn as needed to fund acquisitions. The drawn funds would
be secured by the acquired asset and the debt can be repaid in
stock at $0.10 per share. A second acquisition of a CBD
Infused Confections operation is underway. PURA is currently
working to build a pipeline of more acquisition
opportunities.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024